Condition: Metastatic Renal Cell Carcinoma · Sponsor: Consorzio Oncotech
This phase II open label trial randomized patients who completed the induction with nivolumab plus ipilimumab without complete response or progressive disease will be randomized 1:1 to receive axitinib in addition to nivolumab (Arm A) or continue with nivolumab alone (Arm B).Treatment will be continued until progression of disease, unacceptable toxicity, patient's refusal, or physician decision whichever occurred first.
This description comes directly from the study's public registry record.
Roberto Iacovelli, MD · +393339516295 · roberto.iacovelli@policlinicogemelli.it
Axin Service · axin@oncotech.org
Always discuss trial participation with your own doctor first.
| ASST degli Spedali Civili di Brescia | Brescia, Italy | Not Yet Recruiting |
| Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS | Candiolo, Italy | Not Yet Recruiting |
| Azienda Ospedaliera per l'emergenza Cannizzaro | Catania, Italy | Not Yet Recruiting |
| ASST di Cremona | Cremona, Italy | Not Yet Recruiting |
| Azienda Ospedaliero Universitaria Careggi | Florence, Italy | Not Yet Recruiting |
| Ospedale Policlinico San Martino | Genova, Italy | Not Yet Recruiting |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan, Italy | Not Yet Recruiting |
| Istituto Europeo di Oncologia - IEO | Milan, Italy | Not Yet Recruiting |
| A.O.U. Policlinico di Modena | Modena, Italy | Not Yet Recruiting |
| Policlinico Duilio Casula - Azienda Ospedaliero-Universitaria di Cagliari | Monserrato, Italy | Not Yet Recruiting |
| Azienda Ospedaliero-Universitaria Maggiore della Carità | Novara, Italy | Not Yet Recruiting |
| Istituto Oncologico Veneto | Padova, Italy | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05817903